Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 7/20 | 0.61 |
| ▸ | HTR1A | P08908 | 6/20 | 0.61 |
| ▸ | HTR2C | P28335 | 5/20 | 0.61 |
| ▸ | HTR2B | P41595 | 4/20 | 0.61 |
| ▸ | HTR6 | P50406 | 5/20 | 0.60 |
| ▸ | HTR1B | P28222 | 4/20 | 0.60 |
| ▸ | HTR7 | P34969 | 4/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.60 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.60 |
| ▸ | MAOA | P21397 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N,N-Dimethyltryptamine SCHEMBL31322057 | 0.92 | MEN1 (0.58) | MEN1KMT2AALDH1A1CYP3A4KDM4E | |
| N,N-Dimethyltryptamine SCHEMBL25204923 | 0.90 | HTR2A (0.66) | MEN1KMT2AALDH1A1CYP3A4KDM4E | |
| N,N-Dimethyltryptamine SCHEMBL22772906 | 0.87 | MEN1 (0.65) | MEN1KMT2AALDH1A1CYP3A4KDM4E | |
| N,N-Dimethyltryptamine SCHEMBL22772908 | 0.87 | HTR1A (0.71) | MEN1KMT2AALDH1A1CYP3A4KDM4E | |
| N,N-Dimethyltryptamine SCHEMBL22736733 | 0.87 | HTR2A (0.77) | MEN1KMT2AALDH1A1CYP3A4KDM4E | |
| N,N-Dimethyltryptamine SCHEMBL22736729 | 0.87 | MEN1 (0.65) | MEN1KMT2AALDH1A1CYP3A4KDM4E | |
| N,N-Dimethyltryptamine SCHEMBL30483454 | 0.81 | HTR2A (0.58) | MEN1KMT2AALDH1A1CYP3A4KDM4E | |
| N,N-Dimethyltryptamine SCHEMBL30448862 | 0.81 | MEN1 (0.57) | MEN1KMT2AALDH1A1CYP3A4KDM4E | |
| N,N-Dimethyltryptamine SCHEMBL22736734 | 0.80 | MEN1 (0.65) | MEN1KMT2AALDH1A1CYP3A4KDM4E | |
| N,N-Dimethyltryptamine SCHEMBL22736730 | 0.80 | HTR2A (0.71) | MEN1KMT2AALDH1A1CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220313660-A1 | INJECTABLE FORMULATIONS | SMALL PHARMA LTD (GB) | 2022-10-06 | — | — | US | claimed |
| US-20220168275-A1 | THERAPEUTIC COMPOSITIONS COMPRISING DEUTERATED OR PARTIALLY DEUTERATED N,N-DIMETHYLTRYPTAMINE COMPOUNDS | SMALL PHARMA LTD (GB) | 2022-06-02 | — | — | US | claimed |
| US-20200390746-A1 | Therapeutic Compounds | SMALL PHARMA LTD (GB) | 2020-12-17 | — | — | US | claimed |
| EP-4463440-A1 | TRYPTAMINE COMPOSITIONS AND METHODS | Cybin IRL Limited (IE) | 2024-11-20 | — | — | EP | disclosed |
| US-20240342126-A1 | HALLUCINOGEN-FATTY ACID COMBINATION | MINDSET PHARMA INC. (CA) | 2024-10-17 | — | — | US | disclosed |
| US-12042564-B2 | Therapeutic solid dosage forms | CYBIN UK LTD (GB) | 2024-07-23 | — | — | US | disclosed |
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2024-05-23 | — | — | US | disclosed |
| CN-116056763-B | Therapeutic compositions comprising deuterated or partially deuterated N, N-dimethyltryptamine compounds | 赛本英国有限公司 | 2024-03-05 | — | — | CN | disclosed |
| US-20240016782-A1 | INHALABLE FORMULATIONS | CYBIN UK LTD (GB) | 2024-01-18 | — | — | US | disclosed |
| EP-4275753-A2 | DEUTERATED OR PARTIALLY DEUTERATED N,N-DIMETHYLTRYPTAMINE COMPOUNDS | Small Pharma Ltd (GB) | 2023-11-15 | — | — | EP | disclosed |
| US-20230330063-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2023-10-19 | — | — | US | disclosed |
| US-20210403426-A1 | DEUTERATED N,N-DIMETHYLTRYPTAMINE COMPOUNDS | SMALL PHARMA LTD (GB) | 2021-12-30 | — | — | US | disclosed |
| US-20210378969-A1 | THERAPEUTIC SOLID DOSAGE FORMS | SMALL PHARMA LTD. (GB) | 2021-12-09 | — | — | US | disclosed |
| EP-3902541-A2 | DEUTERATED COMPOUNDS | Small Pharma Ltd (GB) | 2021-11-03 | — | — | EP | disclosed |
| WO-2021116503-A2 | DEUTERATED COMPOUNDS | SMALL PHARMA LTD (GB) | 2021-06-17 | — | — | WO | disclosed |
| EP-3826632-A1 | THERAPEUTIC COMPOSITIONS COMPRISING DEUTERATED OR PARTIALLY DEUTERATED N,N-DIMETHYLTRYPTAMINE COMPOUNDS | Small Pharma Ltd (GB) | 2021-06-02 | — | — | EP | disclosed |
| US-20200397752-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | Consejo Superior de Investigacions Cientificas (CSIS) (ES) | 2020-12-24 | — | — | US | disclosed |
| US-20200390746-A1 | Therapeutic Compounds | SMALL PHARMA LTD (GB) | 2020-12-17 | — | — | US | disclosed |
| US-20200390746-A1 | Therapeutic Compounds | SMALL PHARMA LTD (GB) | 2020-12-17 | — | — | US | disclosed |
| WO-2020245133-A1 | THERAPEUTIC COMPOSITIONS COMPRISING DEUTERATED OR PARTIALLY DEUTERATED N,N-DIMETHYLTRYPTAMINE COMPOUNDS | SMALL PHARMA LTD (GB) | 2020-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12042564-B2 | Therapeutic solid dosage forms | SLC6A4, HTR5A, SLC6A3 | MEN1 442/4885KMT2A 625/4885ALDH1A1 2236/4885 |
| US-20200397752-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | MEN1 3080/4885KMT2A 344/4885ALDH1A1 1445/4885 |
| US-20230330063-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | MEN1 3137/4885KMT2A 305/4885ALDH1A1 1354/4885 |
| US-20240342126-A1 | HALLUCINOGEN-FATTY ACID COMBINATION | FAAH, HTR5A, FAAH2 | MEN1 1324/4885KMT2A 1032/4885ALDH1A1 1852/4885 |
| US-20220313660-A1 | INJECTABLE FORMULATIONS | SLC6A4, HTR5A, SLC6A3 | MEN1 125/4885KMT2A 1550/4885ALDH1A1 2999/4885 |
| US-20210403426-A1 | DEUTERATED N,N-DIMETHYLTRYPTAMINE COMPOUNDS | TPH1, DRD4, TPH2 | MEN1 751/4885KMT2A 1380/4885ALDH1A1 4587/4885 |
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | MEN1 3080/4885KMT2A 344/4885ALDH1A1 1445/4885 |
| US-20240016782-A1 | INHALABLE FORMULATIONS | HTR2B, TPH1, HTR1B | MEN1 849/4885KMT2A 1523/4885ALDH1A1 3126/4885 |
| US-20200390746-A1 | Therapeutic Compounds | HTR5A, DRD4, DRD2 | MEN1 1286/4885KMT2A 2140/4885ALDH1A1 2084/4885 |
| US-20210378969-A1 | THERAPEUTIC SOLID DOSAGE FORMS | SLC6A4, HTR5A, SLC6A3 | MEN1 442/4885KMT2A 625/4885ALDH1A1 2236/4885 |
| US-20220168275-A1 | THERAPEUTIC COMPOSITIONS COMPRISING DEUTERATED OR PARTIALLY DEUTERATED N,N-DIMETHYLTRYPTAMINE COMPOUNDS | DRD2, CHRND, HTR5A | MEN1 1267/4885KMT2A 1778/4885ALDH1A1 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.